$INM Q1 '27 Earnings Results & Recap
InMed Pharmaceuticals expects its $1.1M of cash, cash equivalents and short-term investments at September 30, 2026, to fund operating expenses and capital expenditures into the fourth quarter of calendar 2026, depending on expense levels.